<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Chest</journal-id><journal-id journal-id-type="iso-abbrev">Chest</journal-id><journal-id journal-id-type="pmc-domain-id">886</journal-id><journal-id journal-id-type="pmc-domain">chest</journal-id><journal-title-group><journal-title>Chest</journal-title></journal-title-group><issn pub-type="ppub">0012-3692</issn><issn pub-type="epub">1931-3543</issn><publisher><publisher-name>American College of Chest Physicians</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10083128</article-id><article-id pub-id-type="pmcid-ver">PMC10083128.1</article-id><article-id pub-id-type="pmcaid">10083128</article-id><article-id pub-id-type="pmcaiid">10083128</article-id><article-id pub-id-type="pmid">36343688</article-id><article-id pub-id-type="doi">10.1016/j.chest.2022.10.029</article-id><article-id pub-id-type="pii">S0012-3692(22)04044-2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>COPD: Original Research</subject></subj-group></article-categories><title-group><article-title>Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>LeMaster</surname><given-names initials="WB">W. Blake</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Quibrera</surname><given-names initials="PM">P. Miguel</given-names></name><degrees>MS</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Couper</surname><given-names initials="D">David</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Tashkin</surname><given-names initials="DP">Donald P.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Bleecker</surname><given-names initials="ER">Eugene R.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Doerschuk</surname><given-names initials="CM">Claire M.</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Ortega</surname><given-names initials="VE">Victor E.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Cooper</surname><given-names initials="C">Christopher</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Han</surname><given-names initials="MK">MeiLan K.</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Woodruff</surname><given-names initials="PG">Prescott G.</given-names></name><degrees>MD, MPH</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>O&#8217;Neal</surname><given-names initials="WK">Wanda K.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Anderson</surname><given-names initials="WH">Wayne H.</given-names></name><degrees>MEd, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Alexis</surname><given-names initials="NE">Neil E.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Bowler</surname><given-names initials="RP">Russell P.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Barr</surname><given-names initials="RG">R. Graham</given-names></name><degrees>MD, DrPH</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Kaner</surname><given-names initials="RJ">Robert J.</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Dransfield</surname><given-names initials="MT">Mark T.</given-names></name><degrees>MD</degrees><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Paine</surname><given-names initials="R">Robert</given-names><suffix>III</suffix></name><degrees>MD</degrees><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Kim</surname><given-names initials="V">Victor</given-names></name><degrees>MD</degrees><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Curtis</surname><given-names initials="JL">Jeffrey L.</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au21"><name name-style="western"><surname>Martinez</surname><given-names initials="FJ">Fernando J.</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au22"><name name-style="western"><surname>Hastie</surname><given-names initials="AT">Annette T.</given-names></name><degrees>PhD</degrees><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au23"><name name-style="western"><surname>Barjaktarevic</surname><given-names initials="I">Igor</given-names></name><degrees>MD, PhD</degrees><email>ibarjaktarevic@mednet.ucla.edu</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, Nashville, TN</aff><aff id="aff2"><label>b</label>University of North Carolina, Chapel Hill, NC</aff><aff id="aff3"><label>c</label>Division of Pulmonary and Critical Care Medicine, UCLA, Los Angeles, CA</aff><aff id="aff4"><label>d</label>Department of Medicine, University of Arizona, Tucson, AZ</aff><aff id="aff5"><label>e</label>Division of Respiratory Medicine, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ</aff><aff id="aff6"><label>f</label>University of Michigan School of Medicine, Ann Arbor, MI</aff><aff id="aff7"><label>g</label>Department of Medicine, University of California, San Francisco, San Francisco, CA</aff><aff id="aff8"><label>h</label>National Jewish Health, Denver, CO</aff><aff id="aff9"><label>i</label>Presbyterian Hospital, Columbia University Medical Center, New York, NY</aff><aff id="aff10"><label>j</label>Weill Cornell Medical College, New York, NY</aff><aff id="aff11"><label>k</label>University of Alabama Birmingham and Birmingham VA Medical Center, Birmingham, AL</aff><aff id="aff12"><label>l</label>University of Utah, Salt Lake City, UT</aff><aff id="aff13"><label>m</label>Department of Thoracic Medicine and Surgery, Temple Lung Center, Philadelphia, PA</aff><aff id="aff14"><label>n</label>Medical Service, VA Ann Arbor Healthcare System, Ann Arbor, MI</aff><aff id="aff15"><label>o</label>Atrium Health Wake Forest Baptist, School of Medicine, Winston Salem, NC</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label><bold>CORRESPONDENCE TO:</bold> Igor Barjaktarevic MD, PhD <email>ibarjaktarevic@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2022</year></pub-date><volume>163</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">430733</issue-id><fpage>515</fpage><lpage>528</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-01 00:25:10.097"><day>01</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder/></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) considers blood eosinophil counts&#160;&lt; 100 cells/&#956;L (BEC<sub>&#8804;100</sub>) in people with COPD to predict poor inhaled corticosteroid (ICS) responsiveness. However, the BEC<sub>&#8804;100</sub> phenotype is inadequately characterized, especially in advanced COPD.</p></sec><sec><title>Research Question</title><p>Are there differences between GOLD group D patients with high BEC and those with low BEC regarding baseline characteristics and longitudinal outcomes?</p></sec><sec><title>Study Design and Methods</title><p>We used multivariable mixed models and logistic regression to contrast clinical characteristics and outcomes of BEC<sub>&#8804;100</sub> vs&#160;BEC &gt; 100 (BEC<sub>100+</sub>) in all subjects with COPD (n&#160;= 1,414) and GOLD group D subjects (n&#160;= 185) not receiving ICS.</p></sec><sec><title>Results</title><p>We identified n&#160;= 485 with BEC<sub>&#8804;100</sub> (n&#160;= 61 GOLD group D) and n&#160;= 929 people with BEC<sub>100+</sub> (n&#160;= 124 GOLD group D). BEC<sub>&#8804;100</sub> status was stable at 6&#160;weeks and approximately 52&#160;weeks (intraclass correlations of 0.78 and 0.71, respectively). Compared with BEC<sub>100+</sub>, BEC<sub>&#8804;100</sub> comprised more women, with greater current smoking, and less frequent childhood asthma. Among all analyzed participants, the two BEC-defined subsets showed similar rates of lung function decline (mean slope, BEC<sub>&#8804;100</sub> vs&#160;BEC<sub>100+</sub>, &#8211;50 vs&#160;&#8211;39&#160;mL/y; <italic toggle="yes">P</italic>&#160;= .140), exacerbations (0.40 vs&#160;0.36/y; <italic toggle="yes">P</italic>&#160;= .098), subsequent ICS initiation (2.5%&#160;vs&#160;4.4%; <italic toggle="yes">P</italic>&#160;= .071), and mortality (7.8%&#160;vs&#160;8.4%; <italic toggle="yes">P</italic>&#160;= .715). However, in GOLD group D, people with BEC<sub>&#8804;100</sub> showed higher exacerbation rates within 365&#160;days of enrollment (0.62 vs&#160;0.33/y; <italic toggle="yes">P</italic>&#160;= .002) and total follow-up (1.16 vs&#160;0.83/y; <italic toggle="yes">P</italic>&#160;= .014). They also had greater lung function decline (mean slope of &#8211;68&#160;mL/y vs&#160;&#8211;23&#160;mL/y; <italic toggle="yes">P</italic>&#160;= .036) and had greater emphysema at baseline (voxels&#160;&lt; 950 Hounsfield units at total lung capacity of 7.46%&#160;vs&#160;4.61%; <italic toggle="yes">P</italic>&#160;= .029).</p></sec><sec><title>Interpretation</title><p>In non-ICS-treated GOLD group D COPD, people with BEC<sub>&#8804;100</sub> had more baseline emphysema, prospective exacerbations, and lung function decline. Our analysis has identified a particularly vulnerable subpopulation of people with COPD, suggesting the need for studies focused specifically on their therapeutic treatment.</p></sec><sec><title>Clinical Trial Registration</title><p>ClinicalTrials.gov; No.: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01969344">NCT01969344</ext-link>; URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" id="intref0010">www.clinicaltrials.gov</ext-link></p></sec></abstract><kwd-group id="kwrds0010"><title>Key Words</title><kwd>COPD</kwd><kwd>eosinophil</kwd><kwd>GOLD group D</kwd><kwd>inhaled corticosteroid</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0035">6MWD</term><def><p>6-minute walk distance</p></def></def-item><def-item><term id="kwrd0045">AECOPD</term><def><p>acute exacerbation of the respiratory symptoms of COPD</p></def></def-item><def-item><term id="kwrd0055">BD</term><def><p>bronchodilator</p></def></def-item><def-item><term id="kwrd0065">BEC</term><def><p>blood eosinophil count</p></def></def-item><def-item><term id="kwrd0075">CAT</term><def><p>COPD Assessment Test</p></def></def-item><def-item><term id="kwrd0085">GOLD</term><def><p>Global Initiative for Chronic Obstructive Lung Disease</p></def></def-item><def-item><term id="kwrd0095">ICC</term><def><p>intraclass correlation coefficient</p></def></def-item><def-item><term id="kwrd0105">ICS</term><def><p>inhaled corticosteroid</p></def></def-item><def-item><term id="kwrd0115">SGRQ</term><def><p>St. George&#8217;s Respiratory Questionnaire</p></def></def-item><def-item><term id="kwrd0125">SPIROMICS</term><def><p>Subpopulations and Intermediate Outcome Measures in COPD Study</p></def></def-item></def-list></front></article></pmc-articleset>